UM1 THRU-HOLE CRYSTAL FEATURES OPTIONS & ORDERING
UM1. THRU-HOLE CRYSTAL. FEATURES. High Precision availability. Wide Frequency Range. One day delivery. Applications: Telecommunication equipment Pagers
UM1 FOA Diagram
CTSA Program UM1 Hub. Application Structure. Required and Optional Career. Training and Research Education. Opportunities. Resources Provided by NCATS.
Series One Micro OM Cvr
Congratulations on purchasing the Samson UM1 micro diversity receiver—part of our renowned UHF Series One Wireless System! Although this product is designed
drawing template Insulator 706-TFL-UM1
SIGNATURES. DRN BL. 7/13/2011. CHK RC. 7/13/2011. REVISIONS. DATE. DESCRIPTION. DATE. SHEET 1 OF 1. UM-1 Base Insulator. ECS INC. INTERNATIONAL.
UM1-5C-1 Pad Assembly Model (1)
Page 1. 6". 6" LONG. "C" CHANNEL. CAST IN. (2 TYP.) 14 1/2". FOR COMPLETE DESIGN. AND PRODUCT INFORMATION. CONTACT JENSEN PRECAST. 3/31/04. UM1-5C-1 Pad
To: NCI CTEP UM1 Clinical Trials Investigators From: Richard
23 sept 2022 Dear UM1 Investigators. As part of the iadademstat clinical development program
EFD/EFDB Series Factory Sealed Push Button Stations
EFDCB150-UM1. 3/4. EFDB175-UM1. EFDCB175-UM1. 1. EFDB110-UM1. EFDCB110-UM1. 2-Gang † — Momentary Contact. 1/2. 2 Circuits. Universal. Start/Stop. EFD250-U1.
Cross Reference - U.S. Components U.S. Components/Vishay Dale
UM1-9M. MMP22-9026. UM1-29F1K-DS. MMD1S22-29SK2. UM1-44F1SL-DS. MMD1S22-44SL2. UM1-9M-DS. MMD1P22-9026. UM1-29F1KL. MMS22-29SK2030. UM1-44F2K. MMS22-44SK.
UM1-5C-3 Pad Assembly Model (1)
UM1-5C-3 Pad Assembly.dwg. © 2004 Jensen Precast. 112". FOR COMPLETE DESIGN. AND PRODUCT INFORMATION. CONTACT JENSEN PRECAST. UM1-50-3. 17". LIFTING INSERTS.
PAR-21-293: Clinical and Translational Science Award (UM1
Clinical and Translational Science Award (UM1 Clinical Trial Optional) CTSA UM1 applications from organizations named as a Partner Institution in a funded CTSA UM1 or CTSA UL1 award are not allowed except under rare circumstances with compelling justification UM1 ; June 22 2022 NOT-TR-22-032 : Notice of Change to PAR -21-293 Clinical and
UNDERWRITING MANUAL - eWestcor
UNDERWRITING MANUAL - eWestcor Access 6
Installation and Operation Manual - Microsoft
UM1 1 WARNINGS AND COMPLIANCE WARNING! To reduce the risk of fire of electric shock do not expose this apparatus to rain or moisture WARNING! The apparatus shall not be exposed to dripping or splashing and that no objects filled with liquids such as vases shall be placed on apparatus FCC Notes WARNING!
Searches related to um1 PDF
UM1 SERIES MINIATURE RELAY 1 POLE 0 5A (HIGH FREQUENCE SIGNAL SWITCHING) RoHS Compliant FEATURES z Subminiature polarized relay z Excellent high frequency characteristics Isolation : min 60 dB Insertion loss : max 1 dB V S W R : max 1 2 } z High reliability Bifurcated contacts Movable contact: gold overlay
Funded Activities Under The CTSA Program
As part of its annual fiscal year appropriation, NCATS receives funds to support the programs, initiatives and activities of the CTSA Program. Each CTSA-funded institution provides core resources, subject-matter expertise, and training and educational opportunities to support clinical and translational science. Together, these institutions work col...
Current Funding Announcements
NCATS has released the following funding opportunity announcements for the CTSA Program. View all of NCATS’current funding opportunities.
Related Opportunities of Interest
PA-21-345: Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)
Guidance
Grantee Information
What does UM1 stand for?
Part 1. Overview Information National Center for Advancing Translational Sciences ( NCATS) Clinical and Translational Science Award (UM1 Clinical Trial Optional) UM1 Research Project with Complex Structure Cooperative Agreement See Notices of Special Interest associated with this funding opportunity
How do I write an UM1 application?
The UM1 application must describe the overarching goals of each component and the coordination, integration, synergy, and mutual reinforcement of resources between the components. Include a description of the roles of any shared partners and/or collaborators. Limited to THREE pages.
How many pages are required for UM1 hub application?
Limited to THREE pages. Given the clinical and translational science purpose of UM1 hub applications, research involving human subjects is anticipated to be initiated during the grant period; thus: All applicants must answer Yes to the involvement of Human Subjects during the period of award and complete all related sections.
What is the NCATS UM1 program?
The described Program is intended to be of the type of CTS research that the applicant considers to be of high priority. NCATS solicits the submission of one set of companion applications. With this solicitation for the UM1 application, a separate, companion FOA will solicit applications for a required K12 ( NOT-TR-21-030 ).
Page 1 of 2
To:NCI CTEP UM1 Clinical Trials Investigators
From: Richard Piekarz, M.D., Ph.D., IDB, CTEP, NCIS. Percy Ivy, M.D., IDB, CTEP, NCI
Date:September 23, 2022
Re: Iadademstat Pre-Solicitation Applications: Notification to UM1 InvestigatorsDear UM1 Investigators,
As part of the
iadademstat clinical development program, CTEP would like to request pre-solicitation applications from all interested UM1 investigators for selected studies.Iadademstat (ORY-1001) is an oral small-molecule inhibitor of lysine-specific demethylase 1 (LSD1) and
has been granted FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML) and small cell lung carcinoma (SCLC). LSD1 modulates gene expression via demethylation of histone H3 lysine 4 (H3K4) and9 (H3K9), plus non-histone targets such as p53 (Lynch et al., 2012. Expert Opin
Ther Targets
. 16(12):1239-1249). LSD1 also provides a scaffold for assembly of the GFI1/CoRESTtranscriptional repressor complex, which regulates hematopoietic differentiation (Maiques-Diaz et al.,
2018. Cell Rep. 22(13):3641-3659). Overexpression of LSD1 has been detected in hematological
malignancies such as AML (Niebel et al., 2014. Blood. 124(1):151-152) along with solid tumors such asbladder, lung, and colorectal carcinomas (Hayami et al., 2011. Int J Cancer. 128(3):574-586). In cell
lines and mouse models of AML driven by mixed -lineage leukemia gene (MLL) rearrangements, LSD1 inhibition resulted in impairment of the oncogenic transcriptional program and induction of thedifferentiation program (Harris et al., 2012. Cancer Cell. 21(4):473-487). Gene expression shifting from
a proliferation to differentiation signature has also been preclinically characterized in other AML subtypes (McGrath et al., 2016. Cancer Res. 76(7):1975-1988) and SCLC (Mohammad et al., 2015. Cancer Cell. 28(1):57-69) in response to LSD1 blockade. Iadademstat has demonstrated selective LSD1 target engagement and anticancer activity in both AMLand SCLC cell lines (Sacilotto et al., 2021. ACS Pharmacol. Transl. Sci. 4(6):1818-1834). In xenograft
models of acute leukemia and SCLC, iadademstat suppressed cancer growth and improved survival (Maeset al., 2018, Cancer Cell. 33(3):495-511, Augert et al., 2019, and Sci Signal. 12(567):eaau2922). The
first-in-human trial of iadademstat monotherapy found that it was safe and well-tolerated in patients with
relapsed or refractory (R/R) AML when administered at a dose of 140 µg/m2 /d on the first five days of each week in a28-day cycles (EudraCT 2013-002447-29). Time- and exposure-dependent induction of
myeloblast differentiation markers were observed in the dose expansion cohort (n=14), with one patient
exhibiting complete remission with incomplete count recovery (CRi) (Salamero et al., 2020. J Clin Oncol. 8(36):4260-4273). Iadademstat has also been evaluated in two phase 2 single-arm combination trials: the ALICE trial with azacitidine for treatment-naïve AML patients (EudraCT 2018-000482-36), and the CLEPSIDRA trial with platinum-etoposide for second-line SCLC patients (EudraCT 2018-000469-35). In the ALICE trial, an 81% objective response rate was observed in evaluable patients
(n=27) after 42 months of enrollment. CR or CRi was observed in 64% of patients, exhibiting a durable
response greater than 6 months (Salamero et al ., 2022.Poster at EHA).
In the CLEPSIDRA trial,
four out of ten evaluable patients achieved partial response, with a mean duration of response of 4.5 months (Navarro-Mendivil et al., 2020. Ann. Oncol. 31 (suppl 4):S974-S987).Page 2 of 2
The following clinical trials have been selected for this pre-solicitation application: Phase 2 trial of iadademstat in combination with venetoclax and azacitidine in patients with AML. Phase 2 trial of iadademstat in combination with checkpoint inhibitor in patients with SCLC. The following criteria will be used to prioritize study assignment to investigators: Review of a one-page (maximum) summary of the proposed trial that includes objectives, schema, study size, and correlatives.A site's need for trials to meet accrual goals.
The documented ability of the site to achieve acceptable accrual rates in a similar patient population. If your submission includes other sites, it is recommended to include examples of
their documen ted accrual rate as well. If prior accrual track record does not match projected accrual, please explain rationale for the projected accrual estimates. Competing trials. Please do not omit ongoing competing trials but explain mitigating factors (e.g., the trial will be finished, or the trial is accruing a non-competing patient subset). Early Career Investigator (ECI) trials led by an early-career Principal Investigator (PI). The ECI- PI should have a major interest in clinical research and the intention to develop a career in that field. The ECI-PI should also be within 7 years of completion of fellowship training and be a faculty member at an institution with a successful track record in conducting clinical trials.If you are interested in conducting a trial
with iadademstat in any of the above-described settings, please fill out the attached Pre-LOI form and submit it to PreLOIs@tech-res.com by COB October 7, 2022.Please note that in the case of an ECI application, the ECI-PI"s curriculum vitae and letters of mentorship
and institutional commitment must be submitted together with the Pre-LOI application via e-mail. The
Investigational Drug Branch will review the submissions and make a formal request for a full LOI on or
around October 28, 2022.Should you have questions or concerns regarding this process or the solicited iadademstat trials, please
contact Dr. Richard Piekarz at 240-276-6565 or rpiekarz@nih.gov.quotesdbs_dbs31.pdfusesText_37[PDF] université montpellier 3
[PDF] comment ne pas gaspiller l'eau
[PDF] conseils pour éviter le gaspillage de l'eau wikipedia
[PDF] expression écrite sur le gaspillage de leau
[PDF] fahrenheit 451 texte intégral
[PDF] pour ne pas gaspiller l'électricité il ne faut pas
[PDF] pourquoi il ne faut pas gaspiller leau
[PDF] gaspillage de l'eau wikipédia
[PDF] gaspillage de leau conséquences
[PDF] fahrenheit 451 extrait du livre
[PDF] fahrenheit 451 thèmes abordés
[PDF] règles dasepsie en milieu hospitalier
[PDF] fahrenheit 451 analyse contre utopie
[PDF] asepsie soins infirmiers
